| Literature DB >> 26138754 |
Rosalind Raine1, Caoimhe Nic a' Bháird2, Penny Xanthopoulou3, Isla Wallace4, David Ardron5, Miriam Harris6, Julie Barber7, Archie Prentice8, Simon Gibbs9,10, Michael King11, Jane M Blazeby12, Susan Michie13, Anne Lanceley14, Alex Clarke15, Gill Livingston16.
Abstract
BACKGROUND: Multidisciplinary team (MDT) meetings are the core mechanism for delivering mental health care but it is unclear which models improve care quality. The aim of the study was to agree recommendations for improving the effectiveness of adult mental health MDT meetings, based on national guidance, research evidence and experiential insights from mental health and other medical specialties.Entities:
Mesh:
Year: 2015 PMID: 26138754 PMCID: PMC4489364 DOI: 10.1186/s12888-015-0534-6
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
Fig. 1Overview of the consensus development method used
Fig. 2An example of a recommendation included in the questionnaire
Fig. 3An example of a recommendation and rating from Round Two showing the distribution of Round 1 responses in italics above the Likert scale, and the respondent’s own Round 1 rating in red
The 21 recommendations for improving the effectiveness of mental health multidisciplinary team meetings
| Recommendation | Median | Mean absolute deviation from the median (MADM) | |
|---|---|---|---|
| 1 | The primary objective of MDT meetings should be to agree treatment plans for patients. Other functions are important but they should not take precedence | 8 | 0.88 |
| 2 | MDT discussions should result in a documented treatment plan for each patient discussed | 9 | 0.56 |
| 3 | MDT meeting objectives should include locally (as well as nationally) determined goals | 8 | 0.63 |
| 4 | The objectives of MDT meetings should be explicitly agreed, reviewed and documented by each team | 8 | 0.94 |
| 5 | Explaining the function of the MDT meeting should be a formal part of induction for new staff | 9 | 0.44 |
| 6 | There should be a formal mechanism for discussing recruitment to trials in MDT meetings (for example, having clinical trials as an agenda item) | 8 | 0.81 |
| 7 | All Chairs should be trained in chairing skills | 7 | 0.81 |
| 8 | All new patients should be discussed even if a clear protocol exists | 8.5 | 0.94 |
| 9 | Teams should agree what information should be presented for patients discussed | 9 | 0.56 |
| 10 | All new team members should be told what information they are expected to present | 9 | 0.38 |
| 11 | The objectives of the MDT meeting should be reviewed yearly | 9 | 1 |
| 12 | Once a team has established a set of objectives, the MDT should be audited against these | 7.5 | 0.94 |
| 13 | All action points should be recorded electronically | 9 | 0.81 |
| 14 | Implementation of MDT decisions should be audited annually | 8 | 1 |
| 15 | Where an MDT meeting decision is changed, the reason for changing this should be documented | 9 | 0.19 |
| 16 | There should be a named implementer documented with each decision | 9 | 0.38 |
| 17 | Comorbidities should be routinely discussed at MDT meetings | 8 | 0.94 |
| 18 | Patients’ past medical history should routinely be available at the MDT meeting | 8.5 | 0.56 |
| 19 | The MDT should actively seek all possible treatment options, and discuss these with the patient after the meeting | 9 | 0.44 |
| 20 | Patients should be given verbal feedback about the outcome of the MDT meeting | 8.5 | 0.94 |
| 21 | Where it would be potentially inappropriate to share the content of an MDT discussion with the patient the decision not to feedback should be formally agreed and noted at the meeting | 9 | 0.63 |
Recommendations where strength of agreement was agree (median ≥7) but variation in extent of agreement was high (MADM score >1.75)
| Recommendation | Median | Mean absolute deviation from the median (MADM) | |
|---|---|---|---|
| 22 | All teams should have a designated person at each MDT meeting to help identify suitable patients for clinical trials | 7 | 1.88 |
| 23 | Patients should be given feedback on all treatment options, even those rejected by the MDT | 7 | 2.25 |
| 24 | Patients should be able to choose the mode of MDT meeting feedback ( | 7.5 | 2.19 |
Recommendations where strength of agreement was agree (median ≥7) but variation in extent of agreement was moderate (MADM score 1.11-1.75)
| Recommendation | Median | Mean absolute deviation from the median (MADM) | |
|---|---|---|---|
| 25 | MDT meetings should be a forum for recruiting patients to clinical trials | 8 | 1.19 |
| 26 | All MDTs should have a designated (rather than a rotating) Chair for MDT meetings | 7 | 1.75 |
| 27 | All MDTs should have a dedicated MDT coordinator/administrator | 9 | 1.31 |
| 28 | MDT Chairs should attend at least one other MDT meeting to identify approaches to improve their chairing skills | 8 | 1.56 |
| 29 | A patient list should be available for all team members to view in advance of an MDT meeting | 8.5 | 1.31 |
| 30 | Presentations should be explicitly framed in the light of a specific query or issue to be discussed | 8 | 1.13 |
| 31 | All MDTs should be audited through external peer-review | 8.5 | 1.13 |
| 32 | There should be time within MDT meetings to discuss current and emerging research and evidence only in relation to the case discussed | 7.5 | 1.25 |
| 33 | Relevant psychosocial issues for patients presented to each type of MDT should be identified and agreed by the MDT | 7.5 | 1.44 |
| 34 | The MDT member who presents the case should routinely consider psychosocial factors and ensure that relevant information is available at the meeting | 8 | 1.19 |
| 35 | Teams should be explicit about the research evidence that they are drawing on when making a decision in the MDT meeting | 7 | 1.25 |
| 36 | Patients should be given feedback on which professional groups were present when they were discussed at the MDT meeting | 7.5 | 1.69 |
| 37 | Patients should be given feedback every time they are discussed at an MDT meeting | 8 | 1.25 |
| 38 | Patients should be given written feedback about the outcome of the MDT meeting | 7 | 1.63 |
Medians for each disease group: recommendations rated as “uncertain” overalla
| Recommendation | Overall median | Mean absolute deviation from the median (MADM) | Median amongst mental health panellists N = 5 | Median amongst cancer panellists N = 6 | Median amongst heart failure panellists N = 5 | |
|---|---|---|---|---|---|---|
| 39 | The main objectives of MDT meetings should be the same across all chronic diseases | 6.5 | 1.88 | 3 | 7 | 7 |
| 40 | Teaching should be a function of MDT meetings provided it does not add to the length of meetings | 6.5 | 2.31 | 8 | 6 | 5 |
| 41 | Teaching should be a function of MDT meetings even if it means meetings will be longer | 5 | 1.94 | 7 | 6 | 4 |
| 42 | All treatment plans for existing patients should be agreed in an MDT meeting even if a clear protocol exists | 5 | 2.06 | 7 | 5 | 2 |
| 43 | Members should be allowed to not attend as long as someone from their discipline is attending and the member does not have a case to present | 5 | 1.75 | 7 | 4.5 | 6 |
| 44 | A list of people who are required to attend the MDT meeting should be decided locally by the team | 5 | 2.44 | 6 | 2 | 7 |
| 45 | A patient should only be discussed at the MDT meeting when information on comorbidity is available | 4.5 | 2.19 | 2 | 6 | 6 |
| 46 | A designated MDT member should speak to the patient about comorbidities before the patient is discussed at an MDT meeting | 4 | 2.38 | 6 | 3.5 | 3 |
| 47 | Each MDT should identify the most appropriate methods for presenting complete information on comorbidities | 5 | 1.13 | 7 | 5 | 5 |
| 48 | Case presentation should routinely include a brief introduction of the patient and relevant psychosocial characteristics, otherwise the case should not be discussed | 6 | 2.38 | 7 | 4 | 3 |
| 49 | Any MDT member who presents a case should discuss treatment preferences with the patient before the MDT meeting | 5.5 | 2.00 | 7 | 4.5 | 7 |
| 50 | Patient preferences regarding available treatment options should be discussed with the patient after (rather than before) the MDT meeting | 5.5 | 1.63 | 5 | 6 | 8 |
| 51 | Patients should not be presented at the MDT meeting unless there is someone present who has met with them at least once before the meeting, even if this postpones discussion of that patient | 5 | 2.63 | 8 | 2 | 3 |
| 52 | Patients should be given the opportunity to provide information in advance of the MDT meeting to ensure the information presented is accurate and comprehensive | 5 | 2.13 | 7 | 4.5 | 6 |
| 53 | Patients should be able to provide information by having direct access and the ability to modify their medical records | 5 | 2.69 | 7 | 2 | 5 |
| 54 | Patients should be given the option to provide a written summary for the meeting | 5 | 1.88 | 6 | 3.5 | 3 |
| 55 | Patients should be given the option to provide audio recorded input to the meeting | 4.5 | 2.50 | 7 | 1.5 | 3 |
aIn order to illustrate differences, numbers in green indicate agreement; and numbers in red indicate disagreement
Medians for each disease group: recommendations rated “disagree” overalla
| Question | Overall median | Mean absolute deviation from the median (MADM) | Median amongst mental health panellists N = 5 | Median amongst cancer panellists N = 6 | Median amongst heart failure panellists N = 5 | |
|---|---|---|---|---|---|---|
| 56 | MDT meetings should be a forum for brainstorming and giving advice without necessarily reaching a decision | 3 | 1.25 | 3 | 3 | 2 |
| 57 | Only complex cases should be discussed in the MDT meetings (regardless of whether they are new or existing patients) | 3 | 1.31 | 3 | 2 | 3 |
| 58 | It is more important to discuss all patients, even if superficially, than it is to discuss a smaller number of patients in more depth | 3.5 | 1.69 | 2 | 5 | 2 |
| 59 | There should be time within MDT meetings to discuss current and emerging research and evidence which is not specifically related to an individual case | 3.5 | 2.38 | 6 | 3.5 | 3 |
| 60 | Members should be allowed to join the meeting for cases that are relevant to them and leave after the discussion of these | 3 | 1.19 | 3 | 3 | 3 |
| 61 | Patients’ treatment preferences should be routinely discussed at the MDT meeting and if not available the case should not be discussed | 3 | 1.94 | 5 | 4 | 2 |
| 62 | Patient preferences regarding available management options should be reported to the MDT meeting only if the clinician responsible for their care thinks it will alter the decision | 3 | 2.00 | 5 | 3.5 | 2 |
| 63 | Patients should be asked before the MDT how much they want to be involved in decision-making about their treatment | 3 | 1.88 | 3 | 2.5 | 3 |
| 64 | All patients should be told if they are going to be discussed at an MDT meeting before the meeting otherwise they should not be discussed | 2 | 1.88 | 5 | 1 | 2 |
| 65 | All patients should be explicitly given the choice of whether or not to be discussed at the MDT meeting | 1.5 | 1.19 | 2 | 1 | 1 |
| 66 | Patients should not be given an explicit choice, but if they express concern about being discussed at the MDT meeting they should be allowed to opt out | 2 | 1.25 | 2 | 2 | 5 |
| 67 | Patients should be given the option of attending MDT meetings | 1 | 1.19 | 5 | 1 | 1 |
| 68 | Patients should be given MDT meeting feedback only when decisions are made about their care | 3 | 1.06 | 3 | 3 | 5 |
aStrength of agreement was agree for medians 7 - 9; uncertain for medians 4 - 6.5 and disagree for medians 1 - 3.5